Submission Details
| 510(k) Number | K221801 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 21, 2022 |
| Decision Date | June 02, 2023 |
| Days to Decision | 346 days |
| Submission Type | Traditional |
| Review Panel | Toxicology (TX) |
| Summary | Summary PDF |
K221801 is an FDA 510(k) clearance for the ADVIA Centaur? Anti-M?llerian Hormone (AMH), a Anti-m�llerian Hormone Test System (Class II — Special Controls, product code PQO), submitted by Siemens Healthcare Diagnostics, Inc. (Tarrytown, US). The FDA issued a Cleared decision on June 2, 2023, 346 days after receiving the submission on June 21, 2022. This device falls under the Toxicology review panel. Regulated under 21 CFR 862.1092.
| 510(k) Number | K221801 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 21, 2022 |
| Decision Date | June 02, 2023 |
| Days to Decision | 346 days |
| Submission Type | Traditional |
| Review Panel | Toxicology (TX) |
| Summary | Summary PDF |
| Product Code | PQO — Anti-müllerian Hormone Test System |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 862.1092 |
| Definition | An Anti-müllerian Hormone Test System Is An In Vitro Diagnostic Device Intended To Measure Anti-müllerian Hormone In Human Serum And Plasma. The Test Is Intended To Be Used As An Aid For Assessing Ovarian Reserve In Women. |